U.S. Markets closed

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
89.69-0.80 (-0.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close90.49
Open90.82
Bid87.77 x 900
Ask90.59 x 900
Day's Range89.19 - 91.11
52 Week Range62.48 - 110.37
Volume620,282
Avg. Volume1,125,912
Market Cap19.615B
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.89
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est106.40
  • Incyte to Report Third Quarter Financial Results
    Business Wire

    Incyte to Report Third Quarter Financial Results

    Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, November 5, 2020.

  • Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen
    PR Newswire

    Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen

    Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir. This finding was part of additional efficacy and safety data from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) presented today by John Beigel, M.D., associate director for clinical research in the Division of Microbiology and Infectious Diseases at NIAID. These data were presented at a special International Society for Influenza and other Respiratory Virus Diseases Antiviral Group (isirv-AVG) Virtual Conference on 'Therapeutics for COVID-19.' The largest benefits were observed in patients requiring supplemental oxygen (grade 5 on the eight-point ordinal scale) and those who required high-flow oxygen/non-invasive ventilation (grade 6) at baseline.

  • Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics
    Business Wire

    Nimble Announces Strategic Research Collaboration with Incyte to Discover Novel Peptide-Based Therapeutics

    Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas.